Literature DB >> 16036064

Mechanism of action of bisphosphonates.

Alfred A Reszka1, Gideon A Rodan.   

Abstract

In recent years, substantial progress has been made in understanding the mechanism for bisphosphonate suppression of bone turnover. Bisphosphonates can now be distinguished based on their molecular and cellular mechanisms of action. Simple bisphosphonates such as clodronate and etidronate inhibit bone resorption through induction of osteoclast apoptosis. Clodronate, and perhaps etidronate, triggers apoptosis by generating a toxic analog of adenosine triphosphate, which then targets the mitochondria, the energy center within the cell. For nitrogen-containing bisphosphonates, the direct intracellular target is the enzyme farnesyl diphosphate synthase in the cholesterol biosynthetic pathway. Its inhibition suppresses a process called protein geranylgeranylation, which is essential for the basic cellular processes required for osteoclastic bone resorption. Although nitrogen-containing bisphosphonates can induce osteoclast apoptosis, this is not necessary for their inhibition of bone resorption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 16036064     DOI: 10.1007/s11914-003-0008-5

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  44 in total

1.  Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

Authors:  F P Coxon; M H Helfrich; R Van't Hof; S Sebti; S H Ralston; A Hamilton; M J Rogers
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  Alendronate disturbs vesicular trafficking in osteoclasts.

Authors:  A Alakangas; K Selander; M Mulari; J Halleen; P Lehenkari; J Mönkkönen; J Salo; Kalervo Väänänen
Journal:  Calcif Tissue Int       Date:  2001-12-21       Impact factor: 4.333

3.  The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.

Authors:  J C Frith; J Mönkkönen; S Auriola; H Mönkkönen; M J Rogers
Journal:  Arthritis Rheum       Date:  2001-09

4.  Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.

Authors:  H L Benford; J C Frith; S Auriola; J Mönkkönen; M J Rogers
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

5.  Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

Authors:  Petri P Lehenkari; Maarit Kellinsalmi; Juha P Näpänkangas; Kari V Ylitalo; Jukka Mönkkönen; Michael J Rogers; Alex Azhayev; H Kalervo Väänänen; Ilmo E Hassinen
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

6.  Structural requirements for bisphosphonate actions in vitro.

Authors:  E van Beek; M Hoekstra; M van de Ruit; C Löwik; S Papapoulos
Journal:  J Bone Miner Res       Date:  1994-12       Impact factor: 6.741

7.  Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.

Authors:  Y Azuma; H Sato; Y Oue; K Okabe; T Ohta; M Tsuchimoto; M Kiyoki
Journal:  Bone       Date:  1995-02       Impact factor: 4.398

8.  Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

Authors:  S P Luckman; F P Coxon; F H Ebetino; R G Russell; M J Rogers
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

9.  The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts.

Authors:  D Zhang; N Udagawa; I Nakamura; H Murakami; S Saito; K Yamasaki; Y Shibasaki; N Morii; S Narumiya; N Takahashi
Journal:  J Cell Sci       Date:  1995-06       Impact factor: 5.285

Review 10.  Bisphosphonate mechanism of action.

Authors:  Alfred A Reszka; Gideon A Rodan
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

View more
  51 in total

1.  Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Luca Carta; Jason R Cook; Silvia Smaldone; Gabriella Siciliano; Aaron N Rifkin; Harry C Dietz; Daniel B Rifkin; Francesco Ramirez
Journal:  Hum Mol Genet       Date:  2010-09-24       Impact factor: 6.150

2.  Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.

Authors:  S Lou; H Lv; P Yin; Z Li; P Tang; Y Wang
Journal:  Osteoporos Int       Date:  2018-12-11       Impact factor: 4.507

3.  Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.

Authors:  Valeria S Rosso; Sergio H Szajnman; Leena Malayil; Melina Galizzi; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Bioorg Med Chem       Date:  2011-04-01       Impact factor: 3.641

4.  Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.

Authors:  Nadine Hagelauer; Thomas Ziebart; Andreas M Pabst; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

5.  Dynamic visualization of RANKL and Th17-mediated osteoclast function.

Authors:  Junichi Kikuta; Yoh Wada; Toshiyuki Kowada; Ze Wang; Ge-Hong Sun-Wada; Issei Nishiyama; Shin Mizukami; Nobuhiko Maiya; Hisataka Yasuda; Atsushi Kumanogoh; Kazuya Kikuchi; Ronald N Germain; Masaru Ishii
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

6.  Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment.

Authors:  Jayme C Burket; Daniel J Brooks; Jennifer M MacLeay; Shefford P Baker; Adele L Boskey; Marjolein C H van der Meulen
Journal:  Bone       Date:  2012-10-23       Impact factor: 4.398

7.  Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite.

Authors:  Sanjeev J Suratwala; Samuel K Cho; Jonathan J van Raalte; Sang Hyun Park; Sung Wook Seo; Seong-Sil Chang; Thomas R Gardner; Francis Young-In Lee
Journal:  J Bone Joint Surg Am       Date:  2008-10       Impact factor: 5.284

8.  Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

Authors:  Anita V Neutzsky-Wulff; Mette G Sørensen; Dino Kocijancic; Diana J Leeming; Morten H Dziegiel; Morten A Karsdal; Kim Henriksen
Journal:  BMC Musculoskelet Disord       Date:  2010-06-01       Impact factor: 2.362

9.  Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.

Authors:  Marion Recher; Alejandro P Barboza; Zhu-Hong Li; Melina Galizzi; Mariana Ferrer-Casal; Sergio H Szajnman; Roberto Docampo; Silvia N J Moreno; Juan B Rodriguez
Journal:  Eur J Med Chem       Date:  2012-12-20       Impact factor: 6.514

Review 10.  Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women.

Authors:  Natasha Jordan; Maurice Barry; Eithne Murphy
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.